Agape ATP - Synergising Innovation Across Business PillarsATPC Unveils Its Multifaceted Business Pillars to Drive Global Wellness and Sustainability
KUALA LUMPUR, MALAYSIA, 10 OCTOBER 2024 – NASDAQ-listed AGAPE ATP Corporation ("ATPC"), is proud to present its multifaceted business pillars, each driven by a shared vision to make the world a better place. With a strong commitment to sustainability, health, and enhancing quality of life, ATPC has strategically developed six (6) core pillars that work in synergy to address the world’s most pressing challenges, from energy conservation to advanced medical care.
ATPC’s DSY Wellness division focuses on Nutraceuticals and Nutritional Medicine, offering scientifically backed products that promote overall health and wellness. By addressing nutrition from a medical perspective, DSY Wellness aims to empower individuals to prevent and manage health issues through high-quality, natural supplements and solutions.
On the wellness front, Agape Superior Living (“ASL”) leads the way with breakthrough products like ATP2, a cutting-edge anti-ageing supplement that represents a new frontier in the wellness industry. ASL is dedicated to advancing the anti-ageing market, focusing on improving longevity and enhancing vitality. Through ASL, ATPC aims to revolutionise personal well-being, helping people live healthier and longer lives, in Malaysia and throughout the ASEAN region. Various partners are involved in different countries to offer ATP2.
ATPC Green Energy (“AGE”) spearheads ATPC's efforts in the energy sector, with initiatives aiming to provide sustainable energy solutions, reduce environmental impact, and contribute to Malaysia's clean energy transition. Through B&H Intech Solutions, now ATPC Green Energy Sdn. Bhd., realizing energy saving solutions are on the horizon via contract-talks with GLCs (government linked companies); and, with Xiamen Photons Solar Technology Co., Ltd and value chain partner, Fujian Minfa Aluminium Co., Ltd., a Shenzhen Stock Exchange-listed company, installation of photovoltaic systems for Malaysia and ASEAN countries is attainable. With a focus on innovation, AGE’s solar and energy-saving projects are laying the foundation for a greener, more energy-efficient future, making significant strides toward global sustainability. Currently, projects in Selangor and Sabah are developing with fervor and anticipation.
Cedar ATPC brings innovative healthcare solutions through Myofascial Release Therapy and Pain Relief Therapy, providing effective, non-invasive treatments that improve physical well-being. These therapies and products are designed to relieve pain and enhance mobility, offering individuals a better quality of life and empowering them to take control of their health naturally.
In the medical device sector, ATPC’s collaboration with FORMEDIC Technologies Sdn. Bhd. marks a significant step forward in respiratory care. The LEGA device, a pioneering electronic chest percussion device, has been developed to assist patients suffering from chronic obstructive pulmonary diseases (“COPD”) and other respiratory conditions. This cutting-edge medical device exemplifies ATPC’s commitment to advancing healthcare and improving patient outcomes through innovative solutions.
Lastly, recognising the importance of care in the later stages of life, the Senior Living business pillar is dedicated to fostering vibrant Senior Communities that promote healthy and fulfilling lives for the elderly. ATPC’s approach to senior living is focused on creating safe, supportive environments where seniors can thrive socially, physically, and emotionally, enhancing their overall well-being in their golden years.
Prof Dato’ Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC expressed the company’s mission, “At ATPC, we are committed to leveraging our expertise across multiple sectors to create synergies that not only drive business growth but also contribute to making the world a better place. From sustainable energy projects to life-enhancing medical devices and wellness products, each of our business pillars plays a vital role in shaping a future where health, well-being, and sustainability are within reach for all.”
With a diversified portfolio spanning renewable energy, wellness products, healthcare solutions, and senior care, ATPC stands as a forward-thinking company dedicated to positively impacting lives and creating a sustainable future. Through its integrated approach, ATPC is poised to lead the way in transforming how people live, age, and experience healthcare, all while promoting a greener, healthier planet.
Agape
ATPC and FORMEDIC Technologies Announce Strategic Collaboration Innovative Collaboration Brings Advanced Respiratory Solutions to a Global Market
KUALA LUMPUR, 1 OCTOBER 2024 – NASDAQ-listed AGAPE ATP Corporation ("ATPC"), is proud to announce a strategic collaboration with FORMEDIC Technologies Sdn. Bhd. (“FORMEDIC Technologies”) to introduce LEGA, an electronic chest percussion device for respiratory care. This partnership marks a major advancement in respiratory health, as the two companies combine their strengths to address the growing demand for advanced respiratory solutions.
LEGA, FORMEDIC’s flagship product, assists patients with chronic obstructive pulmonary diseases (“COPD”), pneumonia, bronchiectasis, and other lung-related conditions by providing critical support for airway clearance and secretion management. LEGA helps to manage secretion drainage and airway clearance, offering much-needed relief to patients both adults and children, facing respiratory difficulties in both hospital and home care settings. This device has already gained significant traction in the medical field, with close to 2,000 units used in major hospitals and rehabilitation centres in Malaysia and globally.
For ATPC, this collaboration brings opportunities in the fast-growing respiratory care market, estimated to reach USD 25.95 billion in 2024, with a strong growth trajectory, estimating it to hit USD 49.84 billion by 2031 . As respiratory diseases continue to rise globally, this partnership positions ATPC to capitalise on the increasing demand for advanced respiratory solutions, as well as diversifying its wellness portfolio with a proven medical device.
Prof Dato' Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC, said, "The partnership allows ATPC to leverage FORMEDIC’s expertise in healthcare technology and clinical applications and research and development capabilities, aligning with ATPC’s long-term vision of building a holistic wellness ecosystem that encompasses both preventive and curative solutions.
This is an opportunity for us to address a critical global health need. With LEGA, we are expanding our operations into healthcare technology, an area with immense growth potential. We look forward to continue delivering value through innovation and strategic diversification, and at the same time, accelerate ATPC’s growth and market reach, enhancing shareholder value.”
Ng Zim Guan, Director of FORMEDIC Technologies, added, "LEGA is the culmination of years of research and clinical trials, and our partnership with ATPC allows us to reach more patients globally. We aim to redefine respiratory care with cutting-edge solutions and LEGA’s non-invasive, electronic chest percussion technology has already proven to be a vital tool in improving respiratory health. Partnering with ATPC allows us to further scale this technology and reach more patients in need."
In addition to improving lung health, the collaboration will focus on continuous R&D efforts to explore innovations and develop solutions to improve patient outcomes. ATPC and FORMEDIC will jointly develop marketing strategies to position LEGA as the leading respiratory care solution, ensuring greater accessibility to hospitals, rehabilitation centres, and home users globally.
NASDAQ: ATPC | Technical Review 24/09/30Agape ATP Corporation (NASDAQ: ATPC) , a specialist in renewable energy and wellness products, has demonstrated strong support around the $1.90 level following its compliance with Nasdaq listing requirements.
Recent accumulation activity over the past two weeks suggests the potential for a trend reversal, with downside risks mitigated by key moving average (MA) levels providing support. In the short term, we anticipate a possible challenge of the $2.00 level, while our mid-term target remains at $2.89, supported by current technical indicators and momentum.
Agape ATP Launches ATP2, the Future of Health for Ultimate VitalNow Enhanced with 76 Essential Minerals, 20 Amino Acids, and Advanced Enzymes to Support Overall Wellness
KUALA LUMPUR, 23 SEPTEMBER 2024 – NASDAQ-listed AGAPE ATP Corporation ("ATPC"), through its subsidiary, AGAPE Superior Living Sdn. Bhd (“ASL”)., proudly unveils the enhanced version of its wellness flagship supplement, ATP2. This groundbreaking product, improved with advanced scientific developments, is designed to address key health challenges including aging, metabolism, and chronic disease management. ATP2 represents a significant advancement in nutritional science, offering a holistic approach to improving health, boosting energy, and supporting overall well-being.
At the launch, ATPC announced that the company is targeting to sell 5,000 units by the end of the year, driven by the product’s unique blend of plant-based enzymes, minerals, amino acids, and cutting-edge hydrogen acetate technology. ATPC is confident that demand will surge as consumers increasingly seek natural solutions to improve their health and vitality.
Dr. Fernando Cortizo, the President of Research and Development Team of ASL, said, "The future of nutrition is in our ability to reverse the effects of chronic diseases and aging. ATP2 is a supplement which embodies this vision, combining cutting-edge science with a powerful mix of enzymes, minerals, and amino acids. ATP2 is designed to tackle a variety of health concerns. Its unique formulation supports increased energy production by enhancing Nicotinamide Adenine Dinucleotide (“NADH+”) levels in the body.”
ATP2’s enhanced formula integrates an advanced blend of cutting-edge ingredients that include plant-based enzymes, 76 essential minerals, and 20 amino acids, all working synergistically with its core ingredient, hydrogen acetate, a unique component that has been scientifically proven to improve metabolism, reduce inflammation, and assist in reversing the effects of aging. The added ingredient works more effectively to increase cellular health, regulate key bodily functions, and support long-term vitality.
Prof Dato' Sri Dr How Kok Choong, the Founder and Global Group CEO of ATPC, said, "ATP2 plays a critical role in managing blood pressure and blood sugar levels, promoting cardiovascular health and improving gut flora. The product’s anti-aging properties come from its ability to enhance cellular repair, reduce oxidative stress, and stabilize genome function, helping users maintain a youthful, energetic state as they age.”
How added, “This product is a major milestone for ATPC. It reflects our ongoing commitment to innovation in wellness. ATP2’s comprehensive formula addresses some of the most significant health challenges today. With its ability to improve metabolism, manage chronic conditions, and support anti-aging, ATP2 stands out as a transformative solution for anyone looking to enhance their overall health."
The product is locally manufactured, in Malaysia, ensuring the highest quality control, while its formulation incorporates advanced technologies from Australia, the USA, Europe, and Japan. By bringing production closer to home, ATPC can ensure a steady supply of ATP2 to meet consumer demand while maintaining superior quality standards.
As part of ATPC’s mission to align with the UN Sustainable Development Goals (“UNSDG”), particularly in health and well-being, ATP2 is positioned to make a lasting impact on the wellness market. By offering a scientifically backed solution that addresses common health concerns, ATPC reaffirms its role as a leader in sustainable, innovative wellness solutions.
Benzinga: Why Is Agape ATP Stock Jumping Today?Zinger Key Points
Agape ATP’s stock jumps after partnering with Xiamen Photons Solar to develop solar PV systems in ASEAN countries.
The strategic collaboration aims to address grid stability and power supply issues while advancing Sabah's transition to clean energy.
Agape ATP Corporation ATPC shares are trading higher after the company announced it entered into a strategic collaboration with Xiamen Photons Solar Technology, focusing on developing solar photovoltaic mounting systems for Malaysia and ASEAN countries.
The company’s subsidiary, ATPC Green Energy, has formed a strategic collaboration with Xiamen Photons Solar Technology, a value chain partner of Fujian Minfa Aluminium Co., which is listed on the Shenzhen Stock Exchange.
The agreement was signed at Photons Solar’s headquarters in Xiamen, China.
This partnership is timely as ASEAN nations enhance their commitment to a zero-carbon energy future. Regional governments are actively implementing policies to promote renewable energy development and carbon neutrality.
The collaboration between Photons Solar and ATPC Green Energy aims to accelerate these initiatives and drive the transformation of the ASEAN solar market.
How Kok Choong, founder and global group CEO of ATPC, indicated that the collaboration with Photons Solar represents a significant advancement in their efforts to develop solar PV farms in Sabah.
The partnership is expected to tackle key challenges like grid stability and power supply issues, supporting Sabah’s transition to clean and reliable energy.
“This partnership allows us to leverage local insights and advanced technologies, further supporting our commitment to advancing renewable energy goals across the region,” the CEO added.
Technical Review–Agape ATP Corporation (ATPC)
As investors loom over the slowdown in the US market, the Dow Jones had tumbled close to 500 points in a single trading day. With this, our key stock pick, Agape ATP Corporation (ATPC) sees selling pressure, however a strong support was formed around $1.570 key support level (S1). We believe this selling is short term in nature, and both RSI and MACD showed a trade divergence where there is actually accumulation exercise in place for the shares of ATPC in the range of $1.570 ~ $1.800.
We had commenced accumulation around $1.600 level.
